Please login to the form below
Merck Serono
This page shows the latest Merck Serono news and features for those working in and with pharma, biotech and healthcare.
Merck KGaA announces launch of start-up collaboration programme in Asia
Merck KGaA – known as EMD Serono in the US and Canada – has announced the launch of its Uptune programme in Asia, aiming to ‘generate collaboration opportunities’ with early-stage innovative companies. ... lead to ‘instrumental’ business
Latest news
-
Merck KGaA’s Glucophage approved in Europe as first oral diabetic medication for use during pregnancy
Merck KGaA – known as EMD Serono in the US and Canada – has announced in a European work-sharing procedure (WSP) that an extension to the label for metformin products in the ... both the mother and child, with the decision based on data – taken
-
Lundbeck drops Parkinson’s drug acquired in €905m deal
Lundbeck paid 100m upfront for Merck Serono spinout Pexton and foliglurax two years ago, with another 805m tied to development and sales milestones.
-
Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer
Importantly for Merck KGaA and Pfizer, the drug is the first immunotherapy to achieve improvement in overall survival in the first-line setting in bladder cancer. ... Serono. Although Merck KGaA and Pfizer have not revealed the exact details of the
-
EMD Serono allies with ‘free sequencing’ firm Nebula
Free genomic sequencing in exchange for data use. EMD Serono, the US pharma division of Merck KGaA, has formed an alliance with Nebula Genomics, a startup that offers free genome sequencing – ... Our collaboration with EMD Serono is the first
-
Gilead and ViiV among winners at PM Society Digital Awards
Allergan, Glenmark, Grunenthal, Merck Serono, MSD and Novartis and all won Gold as well.
More from news
Approximately 21 fully matching, plus 138 partially matching documents found.
Latest Intelligence
-
Switzerland: a life sciences hub
When Merck acquired Serono, the company also acquired several manufacturing facilities in the canton of Vaud. ... The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline,
-
The search for treatments for Parkinson’s disease
and a decade as senior director of neurodegenerative diseases research at Merck Serono where he served as its leader for in vitro pharmacology in neurology, including in multiple sclerosis, Parkinson’s
-
A rare opportunity
The disappearance of that opportunity combined with changes at Merck following its 10.6bn acquisition of Serono gave Neil the momentum to set up his own consultancy business in 2007. ... He worked for a number of pharma clients, including Eisai and Merck
-
Sustainable solutions
Over the summer Alex was appointed chair of the EMG, taking over from Merck' Serono's David Garmon-Jones, and he says both the EMG and its wider, UK industry counterpart ... In May 2014 it paid $14.2bn for Merck &Co's consumer health unit.
-
Deal Watch October 2015
This month's deal between Merck Serono (Merck KGaA) and BioMarin is a good example of this approach. ... Acquisition - company. 580. Merck Serono/ BioMarin. Kuvan and pegvaliase (Kuvan marketed; pegvaliase p3).
More from intelligence
Approximately 1 fully matching, plus 21 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
Prior to Sobi, Levin held commercial leadership roles of increasing strategic importance at Merck Serono across a number of countries, including the US, Sweden, Switzerland and Israel. ... Jenkins is a biopharma thought leader with over 25 years of
-
Annalisa Jenkins joins biomarker firm PlaqueTec as CEO
Prior to Dimension Therapeutics, Dr Jenskins served as executive vice president, head of global research and development for Merck Serono and she has also had a nearly 15-year career at
-
Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair
Prior to Dimension, Dr Jenkins held multiple leadership positions, including executive vice president, head of global research and development for Merck Serono and senior vice president, head of global medical affairs
-
New Merck Foundation appoints Rasha Kelej
Rasha Kelej has been appointed chief executive officer for Merck KGaA’s non-profit limited liability company, The Merck Foundation. ... Prior to her new position at The Merck Foundation, Kelej has held numerous roles at Merck, including vice president,
-
Kymab appoints its first chief medical officer
Prior to her time at Novartis, Quaratino worked for Merck Serono, where she was responsible for the clinical development of various immunomodulators.
More from appointments
Approximately 5 fully matching, plus 32 partially matching documents found.
Latest from PMHub
-
Havas Lynx Group
Grϋnenthal. Janssen. Lilly. Lundbeck. Merck Serono. Novartis. Novo Nordisk. Pfizer. Roche.
-
The discount is expiring this Friday for CreateHealth's Customer Experience (CX) in Health Summit, May 12 London
Alan How, Head of Devices and Digital. Health Commercial Excellence and Business Intelligence Department, Merck Serono. ... With attendees already registered from GSK, Pfizer, Merck, AZ, Sanofi, GP's, European payers, IDF, RBS, AXA, GE.
-
PM Society Digital Pioneer 2014 joins the emotive team
Having joined from Merck Serono three years ago, Neil has swiftly moved up the ranks of Account Management demonstrating his hard work and natural flair for client service and project management.
-
Merck Serono, Pfizer, Novartis, Janssen and Lilly Meet to Debate the Future of Clinical Trials | eyeforpharma
Senior executives from Sanofi, Pfizer, GSK, Janssen, Amgen, Eli Lilly, Novo Nordisk, Daiichi Sankyo, LEO Pharma and Merck Serono, TEVA pharmaceuticals are all confirmed to speak at this high-level event.
-
Webinar: Prescription Rationale: Physician Research via an iPhone App
Merck Serono and the Research Partnership's paper used the findings from a study using mobile research technology in order to demonstrate how this methodology gives access to individual physicians' thinking
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
